AzTrials
AzTrials

Colorectal CancerNCT05754229

Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy

A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are: How high is the specificity of the AI system when characterizing colorectal polyps Participants will receive a standard colonoscopy, assisted by the artificial… Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
What is being tested?
AI-assisted colonoscopy
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
395 participants
Where
4 sitesDenmark
Study dates
1 Oct 2022to 21 Apr 2026
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Referred for screening colonoscopy due to a positive faecal immunochemical test (FIT) or for
  • Diagnostic colonoscopy due to symptoms/signs or
  • Post-polypectomy surveillance colonoscopy (only patients who had all detected polyps removed in the previous colonoscopy)

Who cannot join

  • Referral for removal of previous detected polyps
  • Emergency colonoscopy
  • Control colonoscopy due to inflammatory bowel disease (IBD)

Trial locations and contacts

4 sites in 1 country.

Denmark4 sites
  • Holbæk Hospital

    Holbæk, 4300

  • Zealand University Hospital

    Køge, 4600

  • Næstved Hospital

    Næstved, 4700

  • Nykøbing Falster County Hospital

    Nykøbing Falster, 4800

Other trials in Denmark

About this study

Official title: Accuracy of Real Time Characterization in Artificial Intelligence-assisted Colonoscopy - A Prospective Quality Assurance Study

The goal of this substudy is to investigate the accuracy of a computer-aided polyp characterization (CADx) system. The main question[s] it aims to answer are:

  • How high is the specificity of the AI system when characterizing colorectal polyps

Participants will receive a standard colonoscopy, assisted by the artificial intelligence (AI) assisted system GI Genius.

Researchers will compare the AI system´s characterization with the histopathology to see how accurate the system is.

Read the detailed description

Colorectal cancer (CRC) is the third most common cancer, and the second most common cause of cancer-related death worldwide. CRC screening is used for detection and removal of precancerous lesions before they develop into cancer. Colonoscopy is regarded being superior to other screening tests, and is therefore used as the golden standard.

Screening colonoscopy is associated with a reduced risk of CRC-related death. Since it is not possible for an endoscopist to determine the histopathology of the polyp with certainty during a colonoscopy, detected pre-malignant lesions should be removed and sent for histological examination. Multiple studies have shown that there is a strong association between findings at the baseline screening colonoscopy and rate of serious lesions at the follow up colonoscopy. Risk factors for adenoma, advanced adenoma and cancer at follow-up colonoscopy are multiplicity, size, villousness, and high degree dysplasia of the adenomas at the baseline screening colonoscopy.

Within the last few years there have been published several randomized controlled trials (RCT) investigating the efficacy of real time computer-aided detection. Studies have shown that AI contributes to a significantly higher adenoma detection rate (ADR), compared colonoscopies without assistance of an AI system.There have been concerns about prolonged colonoscopy time, and increased workload if implementing the AI-system, since the increased detection of small polyps may lead to unnecessary polypectomy.

With the development of computer-aided polyp characterization (CADx) systems, it is possible to use AI for decision support and not only for detection. There is no evidence yet that the CADx system increases the sensitivity for small neoplastic polyps when used by non-expert endoscopists (accredited for standard colonoscopy), but it may improve the clinicians confidence, and increase the specificity for optical diagnosis (Barua et al).

Diminutive polyps (1-5 mm) in the rectosigmoid colon can be left in situ when diagnosed with high confidence with a sensitivity of at least 90% and a specificity of at least 80%. To implement the resect-and-discard strategy, a sensitivity of at least 80% is acceptable. This is recommended by the European Society of Gastrointestinal Endoscopy (ESGE) as a strategy to decrease the unnecessary removal of small polyps with a negligible risk of harbouring cancer. Although the resect-and-discard strategy is assessed to be a safe and cost-effective method, it is important to be cautious with lesions in the right colon due to their malignant potential.

Reliable CADx systems could enable a more targeted removal of neoplastic polyps, while diminutive non-neoplastic polyps could be left behind. The potential excessive workload due to the CADe system could therefore theoretically be avoided by adding the CADx system.

The results so far are promising, suggesting that AI-assisted colonoscopy is superior to conventional colonoscopy when it comes to polyp and adenoma detection. Continued improvement of CADx systems in differentiating the pathology of colorectal lesions is needed, as well as additional clinical studies to assess the potential value of the CADx system.

The overall aim of this research is to investigate the quality, and the possible benefits of AI-assistance in colonoscopy. Hopefully this can contribute to a more accurate, safe, and targeted diagnosis and treatment of patients in the future.

The investigators have designed a quality assurance study to investigate the effect of real time AI-assisted colonoscopy with the CADx system (GI Genius, Medtronic). This study "REG-093-2022" is a substudy to the RCT "REG-092-2022". The investigators wish to evaluate the diagnostic accuracy of the CADx system.

Being tested
AI-assisted colonoscopy
Keywords
Artificial intelligence-assisted colonoscopy, Computer-aided polyp characterization, Colorectal adenoma
Medical subject headings
Colorectal Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AI-assisted colonoscopyDevice

    The patients will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).

Study groups in NCT05754229
Study groupRoleWhat they receive
AI-assisted colonoscopyOtherThe patients in the intervention group will receive an AI-assisted colonoscopy (AIC) using the computer-aided polyp detection and characterization (CADe and CADx) GI Genius (Medtronic).
Receives: Device: AI-assisted colonoscopy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Measured: 5 Months

  2. True negative findings: Non-adenomas (histopathologically verified) characterized as non-adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Measured: 5 Months

  3. False positive findings: Non-adenomas (histopathologically verified) characterized as adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Measured: 5 Months

  4. False negative findings: Adenomas (histopathologically verified) characterized as non-adenomas by the AI system

    Data from the AI system will be compared with the histopathological data for each removed polyp

    Measured: 5 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Mar 2023
  2. Study start1 Oct 2022
  3. Primary completion3 Mar 2023
  4. Study completion21 Apr 2026

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
395 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05754229
Sponsor's protocol ID
REG-093-2022
Status last verified
Aug 2025
First submitted
3 Feb 2023
Last updated
27 Aug 2026
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing AI-assisted colonoscopy in people with Colorectal Cancer and Colorectal Adenoma, run by Ismail Gögenur at 4 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 4 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

True positive findings: Adenomas (histopathologically verified) characterized as adenomas by the AI system (time frame: 5 Months). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in